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Objectives.Theinescapablerelationshipbetweenchronicinﬂammationandcarcinogenesishaslongbeenestablished.Ourobjective
was to investigate COX-2 and NF-κB immunohistochemical expression in a large series of normal epithelium and bladder
carcinomas. Methods. Immunohistochemical methodology was performed on formalin-ﬁxed, paraﬃn-embedded sections from
urinary bladder carcinomas of 140 patients (94 males and 46 females with bladder carcinomas). Results. COX-2 expression
is increased in the cytoplasm of bladder cells, during loss of cell diﬀerentiation (rs = 0.61, P-value <. 001) and in muscle
invasive carcinomas (P-value <. 001). A strong positive association between tumor grade and nuclear expression of NFκBh a s
been established. A positive correlation between COX-2 and nuclear NFκB immunoreactivity was observed. Conclusions.T h e
possible coordinated upregulation of NFκB and COX-2, during bladder carcinogenesis, indicates that agents inhibitors of these
two molecules may represent a possible new treatment strategy, by virtue of their role in bladder carcinogenesis.
1.Introduction
Urothelial carcinoma (UC) of the urinary bladder is the
third most common cancer in men and the 15th most
common cancer in women. UC-related deaths are mainly
caused by the invasive type of the disease [1]. However, the
more frequent form of this carcinoma is either non-invasive
or superﬁcially invasive disease, which is usually curable,
but demonstrates a challenge to the clinician because of its
recurrent nature. Thus, more eﬀective therapies are needed
to prevent recurrence of superﬁcial UC and to inhibit pro-
gression of noninvasive tumors to invasive carcinomas [2].
The inescapable relationship between chronic inﬂamma-
tion and carcinogenesis has long been established and rests
on DNA damage. Chronic inﬂammation is now recognized
as crucial in the pathogenesis of a variety of diseases, such
asarthritis,diabetes,atherosclerosis,Alzheimer’sdisease,and
cancer development, including bladder cancer [3]. To better
understand the importance of chronic inﬂammation in
bladdercancerpathogenesisandprogression,weinvestigated
COX-2 and NF-κB p65 immunohistochemical expression in
a large series of normal epithelium and bladder carcinomas,
and we correlated those ﬁndings with cancer cell diﬀerentia-
tion, tumor grade and stage, and clinical-pathologic features
of bladder cancer patients.
Cyclooxygenase-2 (COX-2) is an enzyme missing from
most healthy tissues, while its presence is well detected
in neoplastic and inﬂammatory foci [4]. As a catalyst of
prostaglandin synthesis, it promotes the aggregation of
inﬂammatory mediators. COX-2 is a phase I enzyme, which2 Advances in Urology
converts inert xenobiotic ingredients of tobacco smoke into
carcinogenic substances [5]. Finally, tumor angiogenesis is
promoted via prostaglandin action. Regulation of COX-
2 expression is another ﬁeld of interest. Two signalling
pathways are intensely studied: the mitogen-activated pro-
tein kinase cascade is activated by numerous extra- or
intracellular events, culminating in COX-2 transcription [6].
The second pathway begins following either interleukin-
1 or tumor-necrosis-factor-mediated cell stimulation, and
terminates with recruitment of Nuclear Factor-κB( N F - κB)
[4].
NFκB is a transcription factor that regulates a multitude
of inﬂammatory genes, including cytokines, chemokines,
adhesion molecules, and acute phase proteins [7]. NFκB
is a complex of two variable subunits of the Rel/NFκB
superfamily RelA(p65), RelB, c-Rel, p100/p52(NFκB2 ) ,
and p105/p50 NFκB. In most cell types, NFκB dimmers
remain in the cytoplasm transcriptionally silent by virtue
of being bound to an inhibitor protein called Inhibitor-
Kappa-B (I-κB) [8]. Activation of IκB kinase in response
to extracellular stimuli, such as oxidative stress, ischemia,
bacteria, and viruses, leads to IκB phosphorylation and
degradation [9]. The liberated NFκB translocates to the
nucleus, where it actively participates in transcription of a
plethora of genes, involved in proliferation, cell survival,
cell adhesion and encoding cytokines, chemokines, cyclin
D, matrix metalloproteinase, factors of angiogenesis and
antiapoptotic proteins [10]. Molecular studies in multiple
myeloma [11], lymphoma [12], breast [13], pancreatic
[14], prostate cancer [15], head and neck squamous cell
carcinoma [16], and colon [17]a n db l a d d e rc a n c e r[ 18]h a v e
demonstrated that NFκBm a yh a v eac r i t i c a lr o l ei nc a n c e r
development and chemoresistance [19].
Carcinogenesis is a complicated multistep process that
gradually deprives normal cells of their natural phenotype,
resulting in tissue disturbance, from which tumor ﬁnally
emerges. The understanding of the molecular mechanisms
involved in the pathogenesis and progression of bladder
cancer may lead to new and more eﬀective strategies for
risk assessment, prevention, early detection, and targeted
treatment [20].
2.MaterialsandMethods
2.1. Clinical Specimens. 140 consecutive patients diagnosed
with urothelial carcinoma (UC) of the urinary bladder by
either biopsies, transurethral resection of bladder tumor
(TURBT), or cystectomies, at the Department of Urology,
School of Medicine, University of Patras, Greece, between
2000 and 2002, were selected for this study. Demographic
information indicated the presence of 94 males and 46
females with a median age of 70 years (range, 23–90 years).
None of the patients had received any preoperative intraves-
ical treatment or systemic chemotherapy. The research was
approved by the University of Patras Institutional Review
Board and by the Local Research Ethics Committee at
University Hospital of Patras, according to the principles laid
down by the Declaration of Helsinki.
Table 1: Clinical proﬁle of the patients. (Figures in parentheses
indicate percentages within histological types.)
Clinicopathologic parameters N% (140p.)
Gender
Male 94 (67%)
Female 46 (33%)
Age 23–90 (70 ±10)
Normal cases 29 (20.7%)
Grade
GI 27 (24.5%)
GII 30 (27%)
GIII 54 (48.5%)
Ts t a g e
Ta 40 (36%)
T1 30 (27%)
T2 26 (23.4%)
T3 9 (8.1%)
T4 6 (5.4%)
Tumors were graded according to the World Health
Organization Classiﬁcation. (1973 WHO grading) [21], even
outdated but urologists are more familiar with that grading
system, and T classiﬁcation [22]. Staging was based on
combination of clinical (cytoscopy, computed tomography,
and ultrasound) and histological data to determine the
absence (Ta) or presence (T1) of invasion of the lamina
propria or invasion into or beyond the detrusor muscle (T2–
T4) as displayed in Table 1.
2.2. Immunohistochemistry. Tissues were ﬁxed in 10%(v/v)
buﬀered formalin and paraﬃn embedded and stored in the
Department of Pathology, School of Medicine, University
of Patras. Serial 5μm sections were obtained for immuno-
histochemical staining and were mounted on positively
charged slides. The primary antibodies used were a mouse
monoclonalIgG1anti-NFκBsubunitp65(anti-NFκBp65(F -
6) Santa Cruz Biotechnology, USA), and a rabbit polyclonal
anti-COX-2 antibody (anti-COX-2, (Sc-7951) Santa Cruz
Biotechnology, USA).
Sections were restored at 37
◦C for 24 hours and dewaxed
in xylene and ethanol, using serial concentrations, 100-
96-80 for 5 minutes each. Endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxide for 15 minutes.
Antigen retrieval was then performed in citrate buﬀer
(0.001M,ph6)bymicrowavingasfollows:2.5minsat500w,
2.5mins at 700w, and 10mins at 300W. After cooling to
room temperature for 20mins, sections were incubated with
blocking serum in TBS (Tris buﬀered saline) for another
20mins. Afterwards sections were incubated with CAS block
(Zymed Laboratories Inc, San Francisco, California, USA)
for 15mins, in order to reduce nonspeciﬁc staining, and
then with the primary antibody for 30mins (diluted 1:100
for p65 and 1:100 for COX-2), and ﬁnally with the Super
Picture Kit (Zymed) for 50mins. For both antigens, DAB
and hematoxylin for the nuclear staining were used. Negative
controls were prepared, substituting Tris-buﬀered saline forAdvances in Urology 3
primary antibody. Known immunostaining positive speci-
mens were used as a positive controls for NFκB and COX-2.
2.3. Evaluation of Immunostaining. Regarding normal tran-
sitional cell epithelium, every eﬀort was made to obtain
data from patients with free medical history, who underwent
biopsies from suspicious lesions (that turned to have no
histopathological abnormalities) of bladder epithelium after
cystoscopy, for investigation of an episode of hematuria.
Immunostained sections were examined under high-power
(x400) microscopy. COX-2 displays cytoplasmic immunore-
activity and p65 subunit of NFκB is either cytoplasmic
or nuclear or both depending on the state of activation.
Therefore, the two cellular compartments were examined
separately. Immunostained sections were evaluated on ﬁve
(5) diﬀerent representative microscopic ﬁelds from each
section at 400x magniﬁcation. At least 1000 cells were
counted in tissue sections obtained from carcinomas. In
tissue sections obtained from normal bladder epithelium,
200–300 cells were counted. For each ﬁeld, a percentage
(%) of positive cells was calculated and the average of
those was taken. The intensity of the immunohistochemical
staining was scored on a four-point scale as follows: − =
negative (<10% of cells with nuclear staining), + = weak
(weak nuclear staining intensity or 10%–50% of cells with
nuclearstaining), ++ = moderate (moderate nuclear staining
intensityand>50%ofcellswithnuclearstaining),and+++=
strong expression (strong nuclear staining intensity and
>50% of cells with nuclear staining) [23]. Two independent
pathologists evaluated and scored all sections using the
scale without prior knowledge of the clinicopathologic char-
acteristics of each case. When interobserver disagreement
was observed, specimens were reassessed by simultaneous
examination by the two pathologists in a double-headed
light microscope. There was no interobserver disagreement
regarding assessments of tumor diﬀerentiation.
2.4.StatisticalAnalysis. Categoricalvariablesarepresentedas
absolute and relative frequencies. Chi-square test (Pearson
or Fisher’s exact) were used to evaluate the relationship
between the histological grade stage and NFκB expression,
grade stage and COX-2 expression, and grade stage and
gender (to assess the association between histological grade
andgenderandalsoage).AllreportedP valueswerebasedon
two-sided hypothesis. P value less than .05 were considered
statisticallysigniﬁcant.Spearmanrankcorrelationcoeﬃcient
(r) was computed in order to estimate the direction and
strength of correlations between histological grade and
NFκB-COX-2 expressions. Also (r) was used for assessing
the relationship between NFκB and COX-2 expressions.
The above-mentioned statistical methods were also applied
separately according to gender or to age groups (<70 years
and ≥70 years of age).
The Cochran-Armitage test for trend was applied in
NFκB and COX-2 in order to examine possible trends of
the two expressions across the ordered levels of tumor grade
stage. The above mentioned statistical methods were also
applied separately according to gender or age groups (<70
years and ≥70 years of age). SPSS software was used for all
analyses (SPSS Inc., 2003, Chicago,5 IL USA).
3. Results and Discussion
COX-2 was consistently detected in the cytoplasm of epithe-
lial cells (Figures 1(a)–1(d)). Cytoplasmic staining of COX-2
manifested a noteworthy variation among histological
categories as depicted in Table 2 and Figure 2(a).O n l y9 . 3 %
(5/54) of Grade III carcinomas lacked COX-2 positivity
whereas 43.4% (23/54) and 18.9% (11/54) of specimens
manifested strong immunostaining. A positive statistical
signiﬁcant correlation was established between tumor grade
and expression of COX-2 (rs = 0.24, P-value <. 001). Only
17.2% (5/29) of normal bladder epithelium presented with
strong nuclear COX-2 immunoreactivity. COX-2 staining
increased with increasing histological stage in the entire
cohort. Speciﬁcally COX-2 expression was positively corre-
lated with T-tumor category and in muscle invasive carci-
nomas (rs = 0.61, P-value <. 001) (Figure 2(b)). Intergroup
comparisons, regarding correlation of clinicopathological
parameters with expression levels of COX-2 were performed.
There was no statistically signiﬁcant correlation.
NFκB epithelial staining was both cytoplasmic (Figures
1(e)–1(f)) and nuclear (Figures 1(g)–1(h)). The immuno-
histochemical expression of NFκB in the cytoplasm varied
according to histologic type and values of immunohisto-
chemical scores for each grade of diﬀerentiation, as depicted
inTable 3.Statisticalanalysisrevealednocorrelationbetween
cytoplasmic expression and tumor grade (Figure 3(a)).
Speciﬁcally, as normal cells progressively gained atypical
characteristics, the cytoplasmic expression of p65 has been
downregulated, without statistical conﬁrmation (Spearman
correlation coeﬃcient r =− 0.012, P value = .890)
AsfarasnuclearstainingofNFκBisc onc erned,apositiv e
correlation between expression and progression of carcino-
genesiswasestablished.Normalepitheliumspecimenslacked
NFκB nuclear staining (Figure 3(a)). The correlation of
molecular expression and tumor grades was investigated
by the Spearman rank correlation coeﬃcient test, which
revealed a strong positive association between histological
grade and nuclear expression of NFκB( P value <. 001). No
correlation was found between nuclear (P value = .205) and
cytoplasmic staining (P value = .483) of NFκBa n dt u m o r
stage (Figure 3(b)). When we compared values concerning
male and female patients, no statistical signiﬁcance was
established either between them (P value = .675), or
between the two age groups (P value = .75).
We further evaluated the correlation between the expres-
sion of COX-2 and NFκB, separately for cytoplasmic and
nuclear localization. When taking into account the total
number of patients participating in this study, no statistically
signiﬁcant association (rs=0.11, value = .208) wasobtained
when correlating nuclear staining of NFκB and cytoplasmic
of COX-2. Similarly, cytoplasmic staining of NFκBh a dn o
correlation with COX-2 (rs =− 0.01, P value = .90). With
regard to the comparison of cytoplasmic expression of NFκB
and COX-2, no correlation was established (Table 4).4 Advances in Urology
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
Figure 1: (a) and (e) Normal bladder epithelium. (a) Epithelial bladder cells exhibit no immunostaining for COX-2 (x200). (e) Strong
positive cytoplasmic and negative nuclear expression for NFκB (x200). (b) and (f) Well-diﬀerentiated UC (Grade I) (b) Epithelial bladder
cellsexhibitweakpositivecytoplasmicimmunostainingforCOX-2(x200).(f)Moderatenuclearandstrongcytoplasmicimmunostainingfor
NFκB(x200).(c)and(g)ModeratelydiﬀerentiatedUC(GradeII).(c)Epithelialbladdercellsexhibitmoderatecytoplasmicimmunostaining
for COX-2 (x200). (g) Strong nuclear and moderate cytoplasmic immunostaining for NFκB (x200). (d) and (h) Poorly diﬀerentiated UC
(Grade III). (d) Epithelial bladder cells exhibit strong cytoplasmic immunostaining for COX-2 (x200). (h) Strong nuclear immunostaining
for NFκB (x200).Advances in Urology 5
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Figure 2: COX-2 in 140 patients participating in the study stratiﬁed by (a) tumor grade and (b) tumor stage. (error bars = standard error of
the value).
Table 2: Correlation of tumor grade with COX-2 immunostaining. High grade of bladder carcinomas exhibited strong COX-2 cytoplasmic
expression. (Spearman correlation coeﬃcient r = 0.24, Pv a l u e<. 001).
Tumor grade Negative Weak Moderate Strong Total (%)
Normal 6 (20.7%) 14 (48.3%) 4 (13.8%) 5 (17.2%) 29 (100.0%)
Grade I 3 (11.1%) 8 (29.6%) 9 (33.3%) 7 (25.9%) 27 (100.0%)
Grade II 1 (3.3%) 5 (16.7%) 16 (53.3%) 8 (26.7%) 30 (100.0%)
Grade III 5 (9.3%) 15 (27.8%) 23 (43.4%) 11 (18.9%) 54 (100.0%)
Total (%) 15 (10.7%) 42 (30.0%) 52 (37.1%) 31 (21.1%) 140 (100.0%)
The present retrospective immunohistochemical study
demonstrated the expression of NFκB and COX-2 in normal
bladderurotheliumandurothelialcarcinomasandexamined
the variation of its expression. We extended our investi-
gation along the tumor grades, using the World Health
Organization (WHO) 1973 grading system, and showed how
the expression of these factors varied along with T-stage,
according to demographic data, gender, and age.
COX-2 expression was signiﬁcantly higher in poorly dif-
ferentiated cells, and this progressive upregulation was par-
allel with the loss of cancer cell diﬀerentiation. Accumulated
epidemiological data suggest that COX-2 overexpression and
enhanced prostaglandin synthesis are characteristics of quite
a few premalignant and malignant conditions throughout
the body [24]. Expression of COX-2 is common in advanced
bladder carcinomas with poor prognostic characteristics,
supporting eﬀorts to initiate clinical trials on the eﬃcacy
of COX-2 inhibitors in the adjuvant treatment of high-
risk urinary bladder cancer [25]. In detail, COX-2 increases
during initiation andpromotion phasesfromnormal epithe-
lium to carcinomas, exhibits a second rise synchronously
with loss of cell diﬀerentiation, and reaches its highest
expression as cells acquireinvasive and metastatic properties.
Persistent expression of COX-2 was noted in a similar study,
since Cyclooxygenase-2 is not expressed in normal bladder
urothelium, and COX-2 overexpression is associated with
pathologicalandmolecularfeaturesofbiologicallyaggressive
disease, suggesting a role for cyclooxygenase-2 in bladder
cancer development and invasion [26]. On the whole, persis-
tent expression of COX-2 in aberrant cells of premalignant
forms leads to prolonged synthesis of carcinogenic factors,
which, via the mechanisms described in the introductory
section, slow down the healing eﬀect of the self-repairing
apparatus [27].
Next we extended our study, to the expression of NFκB,
the “master” regulator of chronic inﬂammation and malig-
nant transformation [28]. Our results indicate an induction
of this key molecule along the carcinogenesis path and the
level of diﬀerentiation (Figures 1(e)–1(h)). We observed that
normal urothelium displayed mainly cytoplasmic p65/RelA
staining whereas in cancer cells p65 was seen in the nucleus.
There was a progressive induction in nuclear p65 subunit of
activated NFκB expression that paralleled the loss of cancer
cell diﬀerentiation, in higher tumor grade and advanced T-
category whereas cytoplasmic staining decreased. Our data
are consonant with previous studies, which also detected
an induced expression of NFκBi nU C[ 18, 29] and in
gastric, colon, and prostatic adenocarcinoma cells [30],
when compared to their normal counterparts. The detailed
mechanism underlying NFκB activation in bladder cancer
remains unclear. NFκB activation is a multistep process
in which several molecules interact to initiate a highly6 Advances in Urology
Table 3: Expression of NFκB, listed separately for cytoplasmic (C) and nuclear (N) localization, in tumor grade of bladder urothelial
carcinomas (UC).
Negative Weak Moderate Strong Total
C NCNCNCN C - N
Normal 2(6.9%) 29(100%) 4(13.8%) −(0%) 16(55.2%) −(0%) 7(38.9%) −(0%) 29(100%)
Grade I 0(0%) 0(0%) 3(11.1%) 7(26.0%) 8(29.6%) 5(18.5%) 16(59.3%) 15(55.5%) 27(100%)
Grade II 1(3.3%) 3 (10.0%) 7(23.4%) 5(16.7%) 9(30.0%) 13(43.3%) 13(43.3%) 9(30.0%) 30(100%)
Grade III 1(1.8%) 7(13.0%) 9(16.7%) 10(18.5%) 26(48.2%) 23(42.6%) 18(33.3%) 14(25.9%) 54(100%)
Total 4(2.9%) 39(27.9%) 23(16.4%) 22(15.7%) 59(42.1%) 41(29.3%) 54(38.6%) 38(27.1%) 140
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Figure 3: NFκB nuclear (white box) and cytoplasmic (black box) expression, stratiﬁed by (a) tumor grade and (b) tumor stage. Nuclear
expression of NFκB was more frequent, during tumor dediﬀerentiation. (error bars = standard error of the value).
Table 4: Coexpression of COX-2 and NFκB of cytoplasmic (C) and
nuclear(N).Positivecorrelationwasestablishedbetweenexpression
of COX-2 and nuclear staining of NFκB during progression of
carcinogenesis.
Expression
Spearman
correlation
coeﬃcient (P
value)
Cochran-Armitage
Test for trend P
value
NFκB( N )v e r s u s
COX-2 0.11 (.208) .160
NFκB( C )v e r s u s
COX-2
−0.01 (.900) .920
coordinated response [31]. The NFκB-inducing kinase in
combination with the increased activity of the IKK kinase
complex could be the possible signaling pathway that results
in the constitutive activation of the NFκB protein in bladder
carcinomas [32]. Concerning the association with gender
and age, p65 content of male and female increased following
the progress of carcinogenesis, with statistical strong correla-
tion, but no diﬀerence was revealed with the comparison of
genders or age (<70–>70).
A further aim of our study was to correlate the presence
of the COX-2 enzyme with the expression of the regulatory
factor NF-κB. No association between COX-2 and cytoplas-
mic or nuclear p65 immunoreactivity was observed. Yet,
several lines of evidence strengthen our suggestion that there
is a positive correlation of COX-2 level and the nuclear
fraction of p65, since these molecules are concurrently
expressed, during carcinogenesis. Obviously, we recognize
the limitations of such a correlation, since the amounts of
both proteins are also associated with the same parameter,
which is histological type. Esophageal carcinomas, originat-
ingfromeithersquamouscellorBarrett’sepithelium,exhibit
coexpression of COX-2 and NF-κB[ 33]. Moreover, Nadjar
et al. [34]h a v ed e m o n s t r a t e dN F - κB-mediated synthesis ofAdvances in Urology 7
COX-2 in brain cells. Lastly, the chemopreventive antioxida-
tive agent selenomethionine attenuates COX-2 expression by
interfering with NF-κB-dependent transcription [35]. Alto-
gether, there is considerable evidence that NF-κB induction
potentiates transcription of COX-2. It is important to note
that particularly in bladder carcinogenesis, this regulatory
coupling may underlie a cascade sequence: initially, cigarette
smokestimulatesNF-κBactivityinbladdercells[18],leading
to overexpression of COX-2, which in turn metabolizes
inoﬀensive smoke substrates into active carcinogens. Among
our other ﬁndings, we noted the presence of cytoplasmic
staining of p65 in the majority of COX-2-negative cases [36].
This was not surprising, inasmuch as NF-κBi su b i q u i t o u s
and serves as a signal integrator, whose activation regulates
the transcription of hundreds of genes, besides COX-2 [37].
4. Conclusions
Clearly the challenge for the future will be to determine
molecular pathways to inhibit protumor functions of the
inﬂammatory response while preserving the antitumor
activities. Of course validation of these results in a larger
number of cases, with detailed follow-up data and the use
of supplementary in vitro studies are mandatory to verify
our assumptions. The induction of COX-2 in combination
with the antiapoptotic properties of NFκBm a yc o n t r i b u t e
to the pathogenesis of UC. Celecoxib, a widely known
selectiveCOX-2inhibitor[38],andcurcumin,aplantextract
with powerful NF-κB-suppressing properties [39], are a
promising treatment approach to the molecular pathology
model described in the present study. The synergistic eﬀect
of the two agents, oﬀering nontoxic celecoxib dosages, has
been conﬁrmed in colon cancer cells [40]. Still, further
basic research to reveal every possible aspect of the network
synthesized by key molecules, such as COX-2 and NF-κB,
may be the secret to a successful clinical outcome of cancer
chemoprevention.
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